Re-Writing the rules for biotherapeutic discovery.
RubrYc Therapeutics, Inc., is a biotechnology company applying proprietary machine-learning and computational biology solutions to discover epitope-selective biotherapeutics. Inspired by recent advances in molecular library synthesis, massively parallel screening and computing, RubrYc is forging a new path for information-driven discovery of therapeutic antibodies. RubrYc Therapeutics, Inc. emerged as the exclusive biotherapeutic partner of immunomics leader HealthTell. In April 2018, RubrYc Therapeutics, Inc. spun out of HealthTell, and has leveraged the RubrYc Discovery Engine technology to advance proprietary discovery programs, and to partner with top-tier pharmaceutical companies that share their mission to expand therapeutic options and improve outcomes with novel, epitope-targeted biotherapeutics.
- Location: San Carlos, CA
- Paladin Initial Investment Date: April 2018